Maviret

Glecaprevir and Pibrentasvir, the active ingredients in Maviret, are direct‑acting antivirals presented as a 300 mg glecaprevir / 120 mg pibrentasvir tablet for oral use. They treat chronic hepatitis C virus infection (genotypes 1‑6) in adults.

GNH USA supplies Maviret as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Maviret is a direct‑acting antiviral indicated for chronic hepatitis C infection across multiple genotypes.

- Chronic hepatitis C (genotype 1): achieves sustained virologic response, effectively clearing the virus. - Chronic hepatitis C (genotypes 2‑4): achieves sustained virologic response, reducing disease progression. - Chronic hepatitis C (genotypes 5‑6): achieves sustained virologic response, improving liver health.

Common Side Effects: - Headache: mild to moderate intensity. - Fatigue: transient tiredness reported by some patients. - Nausea: occasional upset stomach. - Diarrhea: loose stools in a minority of users. - Abdominal pain: mild discomfort in the upper abdomen. - Pruritus: occasional itching.

Serious or Rare Side Effects: - Elevated liver enzymes: may indicate liver injury. - Severe rash or hypersensitivity: requires immediate medical attention. - Hepatic decompensation: rare but serious liver failure. - Anemia: significant drop in red blood cell count. - Jaundice: yellowing of skin or eyes indicating liver dysfunction. - Allergic reactions: including swelling of face or throat.

Before prescribing Maviret, clinicians should consider several safety measures.

- Baseline liver function assessment: obtain hepatic enzyme levels prior to initiation. - Contraindication in moderate/severe hepatic impairment: avoid use in patients with Child‑Pugh B or C. - Monitor for drug‑drug interactions: review concomitant medications that affect CYP3A4. - Pregnancy safety unknown: use only if potential benefit justifies risk. - Breastfeeding caution: insufficient data on excretion in milk. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Maviret has notable interactions that require attention.

Major Interactions (Avoid): - Strong CYP3A inducers (e.g., rifampin, carbamazepine): may markedly reduce drug exposure. - HIV protease inhibitors boosted with ritonavir: can increase exposure and risk of toxicity. - St. John’s wort: potent CYP3A inducer that lowers efficacy.

Moderate Interactions (Monitor Closely): - Statins (e.g., simvastatin, lovastatin): may increase statin plasma levels, raising risk of myopathy. - Antacids containing aluminum or magnesium: can decrease absorption of the tablets. - Certain anticonvulsants (e.g., phenytoin): may alter plasma concentrations of the antivirals.